Corvus Pharmaceuticals to Report Phase 1 Trial Results for Soquelitinib
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2024
0mins
Corvus Pharmaceuticals Inc. has seen its stock price surge by 45.96% in pre-market trading, reaching a 52-week high amid a challenging market environment where the Nasdaq-100 is down 1.79% and the S&P 500 is down 1.46%.
The significant price movement is attributed to the upcoming conference call on January 20, 2026, where the company will report results from cohort 4 of its Phase 1 trial evaluating soquelitinib for moderate to severe atopic dermatitis. This trial is expected to provide critical data that could influence future research and development efforts, showcasing the company's commitment to advancing its lead drug candidate in the immunotherapy sector.
The implications of this announcement are substantial, as positive trial results could enhance investor confidence and drive further interest in Corvus Pharmaceuticals' pipeline, particularly in light of the ongoing Phase 3 trial for relapsed/refractory PTCL. Investors are advised to monitor the outcomes closely, as they may significantly impact the company's market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRVS
Wall Street analysts forecast CRVS stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.170
Low
11.00
Averages
13.33
High
16.00
Current: 15.170
Low
11.00
Averages
13.33
High
16.00
About CRVS
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corvus Pharmaceuticals Insider Purchase Signals Confidence Amid Price Gains
- Insider Purchase: David Scott Moore of Corvus Pharmaceuticals acquired 21,700 common shares through option exercise on June 11, 2026, valued at approximately $250,236, indicating his confidence in the company's future prospects.
- Price Surge Context: Corvus's stock has surged 217% over the past year, rising from $3.71 to $26.95, reflecting strong market demand for its immuno-oncology therapies and positive investor sentiment.
- Ownership Structure Change: Following this transaction, Moore holds 21,700 common shares and 15,000 stock options directly, representing less than 0.03% of total shares outstanding, yet signaling his optimism about the company's performance.
- Future Acquisition Potential: Moore's 15,000 stock options can be exercised after 2027, providing potential for further increases in direct equity exposure, underscoring his confidence in the company's long-term growth trajectory.
See More
David Scott Moore Acquires Corvus Shares Amid Price Gains
- First Acquisition: On June 11, 2026, David Scott Moore acquired 21,700 common shares for approximately $250,000, marking his first investment in Corvus Pharmaceuticals and reflecting confidence in the company despite not having previously bought shares.
- Stock Options Incentive: On the same day, Moore received 15,000 stock options that will vest in a year, indicating a positive outlook for the company's future and potentially driving further stock price appreciation.
- Market Reaction: Moore's purchase comes after Corvus shares have already risen about 9%, showcasing his good timing in the market, which may attract more investor interest in the company.
- Industry Outlook: As a clinical-stage biotechnology firm focused on immuno-oncology, Corvus aims to advance innovative therapies through clinical trials targeting high unmet needs in oncology, enhancing its position in the competitive cancer therapeutics landscape.
See More
Corvus Pharmaceuticals Participates in $13.5 Million Angel Pharma Financing
- Financing Participation: Corvus Pharmaceuticals announced its participation in a $13.5 million financing for Angel Pharmaceuticals Ltd., investing $5 million, which reflects confidence in Angel Pharma's future development as their collaboration partner in China.
- Clinical Trial Support: The funding will support Angel Pharma's ongoing Phase 1b/2 trial of soquelitinib for atopic dermatitis and asthma, which is expected to yield potential clinical data benefits for Corvus.
- Market Potential: Corvus holds a 49% equity stake in Angel Pharma, and as the Chinese inflammation and immunology markets expand, the clinical data from soquelitinib could create significant value for the company.
- Trial Progress: Angel Pharma's atopic dermatitis clinical trial is enrolling patients at several major dermatology centers in China, with preliminary results expected by late 2026, further advancing the market application of soquelitinib.
See More
Adams Street Partners Exits Entire Paymentus Stake for $5.9 Million
- Share Sale Details: Adams Street Partners LLC reported in its SEC filing dated May 15, 2026, that it sold its entire stake of 223,506 shares in Paymentus Holdings for an estimated $5.88 million, based on the average closing price during the first quarter, indicating a significant reduction in confidence in the stock as the fund's quarter-end position fell by $7.06 million.
- Portfolio Concentration: As of the end of March, Adams Street Partners maintained a highly concentrated portfolio with only three stocks, where its largest holding, BillionToOne, constituted 52% of its total assets under management, highlighting a risky reliance on a limited number of investments.
- Paymentus Performance Review: Despite Adams Street's exit from Paymentus, the company reported robust growth in its recent earnings release, with first-quarter revenue surging 30.2% year-over-year to $358.4 million and adjusted earnings rising 50% to $0.21 per share, indicating strong operational momentum.
- Market Outlook Analysis: The recent launch of AI-native Service Commerce tools by Paymentus is expected to further drive growth, and while it was not included in the current top investment stocks identified by analysts, its innovative capabilities in electronic bill payment may attract future investor interest.
See More
Boxer Capital Acquires Significant Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026, valued at approximately $17.55 million, indicating strong confidence in the company.
- Outstanding Stock Performance: As of May 14, 2026, Corvus shares were priced at $13.66, reflecting a 250% increase over the past year, significantly outperforming the S&P 500's 25% gain, showcasing market recognition of its immuno-oncology therapies.
- Strong Financial Position: Corvus ended the quarter with $236.7 million in cash and marketable securities, expected to fund operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: The ongoing Phase 2 trial is expected to enroll around 200 patients, with preliminary data showing that 75% of patients maintained good responses after treatment cessation, indicating potential in the treatment of atopic dermatitis.
See More
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026 for an estimated $17.55 million, indicating strong confidence in the company, particularly as its stock has surged 250% over the past year.
- Quarter-End Position Value: As of March 31, 2026, Boxer Capital's position in Corvus was valued at $16.09 million, reflecting an active investment strategy amidst stock price fluctuations, further solidifying its standing in the biotech sector.
- Financial Overview: Corvus Pharmaceuticals ended Q1 2026 with $236.7 million in cash and marketable securities, with management stating that this funding will support operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: Corvus is conducting a Phase 2 trial expected to enroll approximately 200 patients, with preliminary data showing that 75% of patients maintained effective responses after treatment cessation, indicating potential in immune modulation that may attract further investor interest.
See More
Corvus Pharmaceuticals Insider Purchase Signals Confidence Amid Price Gains
- Insider Purchase: David Scott Moore of Corvus Pharmaceuticals acquired 21,700 common shares through option exercise on June 11, 2026, valued at approximately $250,236, indicating his confidence in the company's future prospects.
- Price Surge Context: Corvus's stock has surged 217% over the past year, rising from $3.71 to $26.95, reflecting strong market demand for its immuno-oncology therapies and positive investor sentiment.
- Ownership Structure Change: Following this transaction, Moore holds 21,700 common shares and 15,000 stock options directly, representing less than 0.03% of total shares outstanding, yet signaling his optimism about the company's performance.
- Future Acquisition Potential: Moore's 15,000 stock options can be exercised after 2027, providing potential for further increases in direct equity exposure, underscoring his confidence in the company's long-term growth trajectory.
See More
David Scott Moore Acquires Corvus Shares Amid Price Gains
- First Acquisition: On June 11, 2026, David Scott Moore acquired 21,700 common shares for approximately $250,000, marking his first investment in Corvus Pharmaceuticals and reflecting confidence in the company despite not having previously bought shares.
- Stock Options Incentive: On the same day, Moore received 15,000 stock options that will vest in a year, indicating a positive outlook for the company's future and potentially driving further stock price appreciation.
- Market Reaction: Moore's purchase comes after Corvus shares have already risen about 9%, showcasing his good timing in the market, which may attract more investor interest in the company.
- Industry Outlook: As a clinical-stage biotechnology firm focused on immuno-oncology, Corvus aims to advance innovative therapies through clinical trials targeting high unmet needs in oncology, enhancing its position in the competitive cancer therapeutics landscape.
See More
Corvus Pharmaceuticals Participates in $13.5 Million Angel Pharma Financing
- Financing Participation: Corvus Pharmaceuticals announced its participation in a $13.5 million financing for Angel Pharmaceuticals Ltd., investing $5 million, which reflects confidence in Angel Pharma's future development as their collaboration partner in China.
- Clinical Trial Support: The funding will support Angel Pharma's ongoing Phase 1b/2 trial of soquelitinib for atopic dermatitis and asthma, which is expected to yield potential clinical data benefits for Corvus.
- Market Potential: Corvus holds a 49% equity stake in Angel Pharma, and as the Chinese inflammation and immunology markets expand, the clinical data from soquelitinib could create significant value for the company.
- Trial Progress: Angel Pharma's atopic dermatitis clinical trial is enrolling patients at several major dermatology centers in China, with preliminary results expected by late 2026, further advancing the market application of soquelitinib.
See More
Adams Street Partners Exits Entire Paymentus Stake for $5.9 Million
- Share Sale Details: Adams Street Partners LLC reported in its SEC filing dated May 15, 2026, that it sold its entire stake of 223,506 shares in Paymentus Holdings for an estimated $5.88 million, based on the average closing price during the first quarter, indicating a significant reduction in confidence in the stock as the fund's quarter-end position fell by $7.06 million.
- Portfolio Concentration: As of the end of March, Adams Street Partners maintained a highly concentrated portfolio with only three stocks, where its largest holding, BillionToOne, constituted 52% of its total assets under management, highlighting a risky reliance on a limited number of investments.
- Paymentus Performance Review: Despite Adams Street's exit from Paymentus, the company reported robust growth in its recent earnings release, with first-quarter revenue surging 30.2% year-over-year to $358.4 million and adjusted earnings rising 50% to $0.21 per share, indicating strong operational momentum.
- Market Outlook Analysis: The recent launch of AI-native Service Commerce tools by Paymentus is expected to further drive growth, and while it was not included in the current top investment stocks identified by analysts, its innovative capabilities in electronic bill payment may attract future investor interest.
See More
Boxer Capital Acquires Significant Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026, valued at approximately $17.55 million, indicating strong confidence in the company.
- Outstanding Stock Performance: As of May 14, 2026, Corvus shares were priced at $13.66, reflecting a 250% increase over the past year, significantly outperforming the S&P 500's 25% gain, showcasing market recognition of its immuno-oncology therapies.
- Strong Financial Position: Corvus ended the quarter with $236.7 million in cash and marketable securities, expected to fund operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: The ongoing Phase 2 trial is expected to enroll around 200 patients, with preliminary data showing that 75% of patients maintained good responses after treatment cessation, indicating potential in the treatment of atopic dermatitis.
See More
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026 for an estimated $17.55 million, indicating strong confidence in the company, particularly as its stock has surged 250% over the past year.
- Quarter-End Position Value: As of March 31, 2026, Boxer Capital's position in Corvus was valued at $16.09 million, reflecting an active investment strategy amidst stock price fluctuations, further solidifying its standing in the biotech sector.
- Financial Overview: Corvus Pharmaceuticals ended Q1 2026 with $236.7 million in cash and marketable securities, with management stating that this funding will support operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: Corvus is conducting a Phase 2 trial expected to enroll approximately 200 patients, with preliminary data showing that 75% of patients maintained effective responses after treatment cessation, indicating potential in immune modulation that may attract further investor interest.
See More
